phrykt

MAIA Biotechnology, Inc. (MAIA): who owns it and who trades it

As of Nov 16, 2026, MAIA insiders reported 25 purchases worth $971K in the last 12 months. The largest buyer was Vlad Vitoc (CEO), with $293K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling MAIA Biotechnology

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MAIA

36 funds and institutions reported MAIA shares worth $19.4M at the end of Q2 2026, about 22% of the company. The largest holder is Solas Capital Management, LLC with 5.0%.

Funds and institutions (13F) 22%Everyone else 78%

10 largest owners, by share of the company

Solas Capital Management, LLC5.0%
Alyeska Investment Group, L.P.4.1%
Vanguard Capital Management LLC4.0%
683 Capital Management, LLC1.8%
Centric Wealth Management1.3%
Cable Car Capital, LP0.8%
Geode Capital Management, LLC0.8%
Bleichroeder LP0.8%
Renaissance Technologies LLC0.7%
BlackRock, Inc.0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Solas Capital Management, LLC3.03M5.00%$4.4M-29%
Alyeska Investment Group, L.P.2.50M4.12%$3.6MNo change
Vanguard Capital Management LLC2.41M3.98%$3.5M+16%
683 Capital Management, LLC1.07M1.76%$1.5MNo change
Centric Wealth Management796,7231.31%$1.1MNo change
Cable Car Capital, LP514,5830.85%$741K-21%
Geode Capital Management, LLC504,3800.83%$727K+40%
Bleichroeder LP500,0000.82%$720KNo change
Renaissance Technologies LLC415,7000.69%$599KNew
BlackRock, Inc.403,0110.66%$580K+215%
Vanguard Fiduciary Trust Co336,6880.55%$485K+69%
State Street Corp201,7500.33%$291K+45%
Bleakley Financial Group, LLC181,6230.30%$262KNew
Northern Trust Corp125,1710.21%$180K+138%
Morgan Stanley104,0170.17%$150K+651%
Bridgeway Capital Management, LLC76,0000.13%$109K+111%
Two Sigma Investments, LP50,3830.08%$72.6KNew
Envestnet Asset Management Inc44,3470.07%$63.9KNew
Susquehanna International Group, LLP35,2230.06%$50.7KNew
Pvg Asset Management Corp34,1350.06%$49.2KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MAIA insiders reported $971K of open-market purchases and $0 of sales.

Purchases, 12 months
$971K
25 trades, 7 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Sep 14, 2026
Filed Sep 15, 2026

Purchases and sales by month

$230K$230KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 14, 2026Vlad VitocCEOPurchase73,000$1.37$100KForm 4
Sep 10, 2026Ramiro GuerreroDirectorPurchase37,595$1.32$49.6KForm 4
Aug 28, 2026Ramiro GuerreroDirectorPurchase46,620$1.35$62.9KForm 4
Aug 27, 2026Ramiro GuerreroDirectorPurchase78,239$1.39$109KForm 4
Aug 26, 2026Ramiro GuerreroDirectorPurchase8,931$1.39$12.4KForm 4
Aug 24, 2026Ramiro GuerreroDirectorPurchase1,794$1.33$2.4KForm 4
Aug 20, 2026Ramiro GuerreroDirectorPurchase11,899$1.37$16.3KForm 4
Jun 1, 2026Vlad VitocCEOPurchase72,700$1.39$101KForm 4
Jun 1, 2026Stan SmithDirectorPurchase75,000$1.34$100KForm 4
Jun 1, 2026Sergei GryaznovChief Scientific OfficerPurchase2,000$1.35$2.7KForm 4
Dec 22, 2025Stan SmithDirectorPurchase57,189$1.22$69.8KForm 4
Dec 22, 2025Steven M ChaoukiDirectorPurchase40,849$1.22$49.8KForm 4
Dec 22, 2025Ngar Yee LouieDirectorPurchase81,699$1.22$99.7KForm 4
Dec 5, 2025Stan SmithDirectorPurchase4,580$1.20$5.5KForm 4
Dec 5, 2025Stan SmithDirectorPurchase4,580$1.19$5.5KForm 4
Nov 28, 2025Vlad VitocCEOPurchase50,000$1.14$57KForm 4
Nov 28, 2025Cristian LuputDirectorPurchase18,145$1.11$20.1KForm 4
Nov 26, 2025Vlad VitocCEOPurchase22,000$1.05$23.1KForm 4
Nov 26, 2025Cristian LuputDirectorPurchase20,000$1.08$21.6KForm 4
Nov 26, 2025Stan SmithDirectorPurchase15,000$1.04$15.6KForm 4
Nov 25, 2025Vlad VitocCEOPurchase10,500$0.97$10.2KForm 4
Nov 25, 2025Cristian LuputDirectorPurchase10,000$0.98$9.8KForm 4
Nov 25, 2025Stan SmithDirectorPurchase15,000$0.98$14.7KForm 4
Nov 24, 2025Stan SmithDirectorPurchase10,000$0.99$9.9KForm 4
Nov 21, 2025Vlad VitocCEOPurchase1,800$0.92$1.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Vlad VitocChief Executive Officer, Director, 10% owner$293K–Sep 14, 2026
Ramiro GuerreroDirector$252K–Sep 10, 2026
Stan SmithDirector$221K–Jun 1, 2026
Ngar Yee LouieDirector$99.7K–Dec 22, 2025
Cristian LuputDirector$51.5K–Nov 28, 2025
Steven M ChaoukiDirector$49.8K–Dec 22, 2025
Sergei GryaznovChief Scientific Officer$2.7K–Jun 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MAIA short interest

Low short interest. 4.0% of MAIA shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went down 13%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.45M MAIA shares were sold short, 4.0% of the shares outstanding, down 2.8% from the report before. At the average daily volume of 271,949 shares, buying them all back would take about 9.0 trading days (days to cover).

Shares short, % of all shares

4.03%May 15Oct 305.95%

Days to cover

9.0May 15Oct 3010.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.45M4.03%-3%271,9499.0
Oct 15, 20262.52M4.15%-6%435,4445.8
Sep 30, 20262.69M4.42%+28%784,6123.4
Sep 15, 20262.10M3.45%-11%569,3713.7
Aug 31, 20262.35M3.86%-15%368,6636.4
Aug 14, 20262.75M4.52%-10%339,8008.1
Jul 31, 20263.06M5.05%+5%453,3446.8
Jul 15, 20262.92M4.81%-14%714,0504.1
Jun 30, 20263.41M5.62%+7%588,3535.8
Jun 15, 20263.18M5.24%+8%1.42M2.2
May 29, 20262.95M4.87%+5%520,6765.7
May 15, 20262.82M4.65%-11%566,8815.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

MAIA Biotechnology company events

MAIA Biotechnology filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 6, 2026.

  1. Oct 6, 2026AnnouncementShared information with investors. Filing
  2. May 22, 2026VoteReported shareholder vote results. Filing
  3. May 14, 2026AgreementEnded an important agreement. Filing
  4. Apr 16, 2026AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer” A copy of the press release is attached hereto as Exhibit… Filing
  5. Apr 8, 2026AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein… Filing
  6. Apr 2, 2026LeadershipThe Board of Directors of MAIA Biotechnology, Inc. approved one-time bonus payments of $312,610 to Vlad Vitoc, the Company’s Chief Executive Officer and $50,000 to Jeffrey Himmelreich, the Company’s Head of Finance, in consideration for their efforts in connection with the Company’s recent capital… Filing
  7. Mar 31, 2026AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by… Filing
  8. Mar 27, 2026AnnouncementReference is made to the disclosure under Item 7.01 above which is hereby incorporated in this Item 8.01 by reference. Filing
  9. Mar 4, 2026AgreementMAIA Biotechnology, Inc. entered into an underwriting agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC, pursuant to which the Company agreed to issue and sell in an underwritten public offering an aggregate of 20,000,000 shares of the Company’s common stock… Filing
  10. Feb 24, 2026AnnouncementMAIA Biotechnology, Inc. issued a 2026 Letter to Shareholders detailing the Company’s development pipeline. Filing
  11. Jan 20, 2026AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines 2026 Clinical Milestones and Growth Momentum” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
  12. Jan 13, 2026AnnouncementReference is made to the disclosure under Item 7.01 above which is hereby incorporated in this Item 8.01 by reference. Filing
  13. Dec 17, 2025AgreementMAIA Biotechnology, Inc. entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of: (i) 1,053,751 shares of the Company’s common stock, par value $0.0001 per share, and (ii) warrants to purchase up to 1,053,751 shares of… Filing
  14. Dec 11, 2025AnnouncementMade another announcement. Filing
  15. Dec 10, 2025AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
  16. Nov 21, 2025AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
  17. Nov 20, 2025AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

MAIA Biotechnology financials

Famous investors that hold MAIA

3 of the 50 well-known investors we track reported holding MAIA in their latest 13F filing. The largest position is Jim Simons's, worth $471K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026399,100$471K0.0%-4%
Ken Griffin · Citadel AdvisorsQ3 2026226,877$268K0.0%+812%
Steve Cohen · Point72 Asset ManagementQ3 202617,175$20.3K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about MAIA Biotechnology, Inc. (MAIA) stock

Who owns the most MAIA stock?

The largest reported owner of MAIA Biotechnology, Inc. (MAIA) is Solas Capital Management, LLC, with 5.0% of the company. In total, 36 funds and institutions reported holding MAIA at the end of Q2 2026, together about 22% of the shares. See the largest owners.

Are MAIA insiders buying or selling?

In the last 12 months, MAIA insiders reported 25 open-market purchases worth $971K and no sales. The latest trade was on Sep 14, 2026. See every trade.

What is the short interest in MAIA?

As of Oct 30, 2026, 2.45M MAIA shares were sold short, 4.0% of the shares outstanding, down 2.8% from the report before. At the average daily volume of 271,949 shares, buying them all back would take about 9.0 trading days (days to cover). See the history.

Which famous investors hold MAIA?

3 of the 50 well-known investors we track reported MAIA in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $471K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.